Table 4.

Factors associated with hospitalizations with a discharge diagnosis of infection within 6 months after rituximab in adult patients with incident primary AIHA

VariablesPatients, nEvents, n6-mo cumulative incidence,
% (95% CI)		Univariable
Cox model		Multivariable
Cox model		Multivariable
Fine-Gray model
csHR95% CIcsHR95% CIsHR95% CI
Total 959 169 18 (15-20) - - - - - - 
Age, ≥70 y 530 126 24 (20-27) 2.90 1.85-4.54 2.74 1.64-4.58 2.12 1.10-4.09 
Male sex 378 70 18 (15-22) 1.31 0.89-1.93 1.25 0.83-1.89 1.19 0.69-2.06 
Charlson Comorbidity Index score∗ of ≥1 438 104 24 (20-28) 1.98 1.33-2.94 1.49 0.95-2.33 0.80 0.46-1.42 
Splenectomy 29 5 17 (6-33) 0.73 0.19-2.81 0.89 0.23-3.43 1.34 0.34-5.39 
Red blood cell transfusions,† ≥1 297 72 24 (19-29) 1.66 1.12-2.46 1.46 0.99-2.16 1.06 0.62-1.80 
Corticosteroids 619 112 18 (15-21) 1.49 1.10-2.03 1.59 1.17-2.17 1.52 1.00-2.33 
Other immunosuppressants‡  43 5 12 (4-23) 1.21 0.36-4.05 1.35 0.41-4.49 2.63 0.80-8.61 
Pneumococcal vaccination 230 30 13 (9-18) 0.65 0.39-1.08 0.74 0.44-1.23 0.86 0.45-1.66 
Influenzae vaccination 354 73 21 (16-25) 1.32 0.89-1.94 0.87 0.58-1.31 0.76 0.45-1.29 
VariablesPatients, nEvents, n6-mo cumulative incidence,
% (95% CI)		Univariable
Cox model		Multivariable
Cox model		Multivariable
Fine-Gray model
csHR95% CIcsHR95% CIsHR95% CI
Total 959 169 18 (15-20) - - - - - - 
Age, ≥70 y 530 126 24 (20-27) 2.90 1.85-4.54 2.74 1.64-4.58 2.12 1.10-4.09 
Male sex 378 70 18 (15-22) 1.31 0.89-1.93 1.25 0.83-1.89 1.19 0.69-2.06 
Charlson Comorbidity Index score∗ of ≥1 438 104 24 (20-28) 1.98 1.33-2.94 1.49 0.95-2.33 0.80 0.46-1.42 
Splenectomy 29 5 17 (6-33) 0.73 0.19-2.81 0.89 0.23-3.43 1.34 0.34-5.39 
Red blood cell transfusions,† ≥1 297 72 24 (19-29) 1.66 1.12-2.46 1.46 0.99-2.16 1.06 0.62-1.80 
Corticosteroids 619 112 18 (15-21) 1.49 1.10-2.03 1.59 1.17-2.17 1.52 1.00-2.33 
Other immunosuppressants‡  43 5 12 (4-23) 1.21 0.36-4.05 1.35 0.41-4.49 2.63 0.80-8.61 
Pneumococcal vaccination 230 30 13 (9-18) 0.65 0.39-1.08 0.74 0.44-1.23 0.86 0.45-1.66 
Influenzae vaccination 354 73 21 (16-25) 1.32 0.89-1.94 0.87 0.58-1.31 0.76 0.45-1.29 

sHR, subdistribution hazard ratio.

∗

Adapted for the French national health database by Bannay et al.11 

†

Number of transfusions between the diagnosis of AIHA and the index date (first infusion of rituximab).

‡

Azathioprine, cyclosporin, and mycophenolate.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal